Alzheimer's disease (AD) is the most common cause of dementia in the elderly. β-Amyloid (Aβ) has been proposed to play a role in the pathogenesis of AD. Deposits of insoluble Aβ are found in the brains of patients with AD and are one of the pathologi...
Cerebrospinal fluid (CSF) concentrations of YKL-40 that serve as biomarker of neuroinflammation are known to be altered along the clinico-biological continuum of Alzheimer's disease (AD). The specific structural cerebral correlates of CSF YKL-40 were...
AJNR. American journal of neuroradiology
Dec 4, 2025
BACKGROUND AND PURPOSE: Identifying amyloid-beta (Aβ)-positive patients is essential for Alzheimer disease clinical trials and disease-modifying treatments but currently requires PET or CSF sampling. Previous MRI-based deep learning models using only...
There is an urgent need for the precise prediction of cerebral amyloidosis using noninvasive and accessible indicators to facilitate the early diagnosis of individuals with the preclinical stage of Alzheimer's disease (AD). Two hundred and four indiv...
With all the advances in both the science of aging and artificial intelligence (AI), we are in a propitious position to accurately and precisely determine who is at high risk of developing Alzheimer's disease years before signs of even mild cognitive...
Alzheimer's & dementia : the journal of the Alzheimer's Association
Mar 1, 2025
BACKGROUND: Integrating non-invasive measures to estimate abnormal amyloid beta accumulation (Aβ+) is key to developing a screening tool for preclinical Alzheimer's disease (AD). The predictive capability of standard neuropsychological tests in estim...
Journal of neuropathology and experimental neurology
Nov 1, 2024
Neuropathologic changes of Alzheimer disease (AD) including Aβ accumulation and neuroinflammation are frequently observed in the cerebral cortex of patients with idiopathic normal pressure hydrocephalus (iNPH). We created an automated analysis platfo...
American journal of Alzheimer's disease and other dementias
Jan 1, 2024
Several research studies have demonstrated the potential use of cerebrospinal fluid biomarkers such as amyloid beta 1-42, T-tau, and P-tau, in early diagnosis of Alzheimer's disease stages. The levels of these biomarkers in conjunction with the demen...
In vivo imaging and accurate identification of amyloid-β (Aβ) plaque are crucial in Alzheimer's disease (AD) research. In this work, we propose to combine the coherent anti-Stokes Raman scattering (CARS) microscopy, a powerful detection technology fo...
Background PET can be used for amyloid-tau-neurodegeneration (ATN) classification in Alzheimer disease, but incurs considerable cost and exposure to ionizing radiation. MRI currently has limited use in characterizing ATN status. Deep learning techniq...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.